Home > Healthcare > Pharmaceuticals > Finished Drug Form > Joint Pain Injections Market

Joint Pain Injections Market Share

Report ID: GMI5403
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Joint Pain Injections Market Share

The market is fragmented in nature, with global, regional, and local small players, and manufacturers playing a key role in the industry competition. Few of the key players operating in the market include DePuy Synthes (Johnson & Johnson), Pfizer Inc., Sanofi SA, Stryker Corporation, Zimmer Biomet, Arthrex, Ferring B.V. and OrthogenRx, among others. The global market is marked by significant competition driven by innovations in product formulations and expanding applications for joint pain relief.

Key players such as Pfizer, Sanofi, Anika Therapeutics, and Zimmer Biomet lead the market, leveraging their established portfolios and R&D capabilities to develop advanced corticosteroids, hyaluronic acid, and other injectables that cater to chronic pain management. Emerging players and specialized companies focus on novel drug delivery systems, expanding treatment efficacy and targeting underserved segments, especially in aging populations. Strategic partnerships, product launches, and regional expansions are common as companies aim to strengthen their global presence.

Joint Pain Injections Market Companies

Key players operating in the joint pain injections industry include:

Anika Therapeutics, Inc.
Arthrex
Bioventus
Emcyte Corporation
Ferring B.V.
Lifecore Biomedical
OrthogenRx
Pacira BioSciences (Flexion)
Pfizer, Inc.
Sanofi S.A.
Stryker Corporation
Zimmer Biomet Holdings, Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global joint pain injections industry was valued at USD 3.6 billion in 2023 and is anticipated to grow at a 7.7% CAGR from 2024 to 2032, driven by an increasing elderly population and a rise in orthopedic issues.

The hyaluronic acid injections segment held a 64.8% revenue share in 2023 and is projected to expand at a 7.9% CAGR during the forecast period due to the aging population and the development of technologically advanced products.

The North America joint pain injections industry held a 47.4% share in 2023 and is set to witness substantial growth, primarily due to the increasing prevalence of arthritis and other bone-related issues, coupled with the rapid adoption of new products.

Key players in the industry include Anika Therapeutics, Inc., Arthrex, Bioventus, Emcyte Corporation, Ferring B.V., Lifecore Biomedical, OrthogenRx, Pacira BioSciences (Flexion), and Pfizer, Inc.